GO
简体中文

Who We Are

BeyondSpring is a Global, Clinical-Stage
Bio-pharmaceutical Company

Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.

Detail



Development

Pipeline

We have a robust drug development pipeline at various clinical and pre-clinical stages.

Read More
NewsMedia

BeyondSpring's Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

Detail

BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

Detail

BeyondSpring Announces Pricing of Ordinary Shares

Detail

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

Detail

BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia

Detail

BeyondSpring's Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors

Detail

Cell Journals Publishes BeyondSpring's New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

Detail

© 大连万春布林医药有限公司. All Rights Reserved.